Crysvita is a medication used to treat X-linked hypophosphatemia (XLH), a rare genetic disease that causes low levels of phosphorus in the bloodstream, leading to symptoms such as stunted growth, weak bones, muscle weakness, and tooth defects. Crysvita is a monoclonal antibody that targets fibroblast growth factor 23 (FGF23), a hormone that regulates phosphorus and Vitamin D levels. Crysvita neutralizes FGF23, allowing phosphorus to be reabsorbed by the kidneys, correcting levels in the bloodstream. Crysvita has been found to be safe and effective, improving bone density and quality of life for patients. It is administered every two weeks as an injection. Crysvita is a significant and innovative treatment option for XLH patients.